🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yiping Zhang

Hebei Medical University

ORCID: 0000-0003-4425-2165

Also affiliated with China National Center for Biotechnology Development, Harrison International Peace Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma”.

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

Cancer(2020)10.1002/cncr.33349

N/A

1.4DataRank · unranked

47 citations

Karla V. Ballman, Lee J. Helman, Shreyaskumar Patel, Jeremy Whelan, Brigitte C. Widemann +9 more

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

Oncogenesis(2020)10.1038/s41389-020-00264-0

N/A

1.2DataRank · unranked

30 citations

Choh Yeung, Sameer H. Issaq, Victor J. Collins, M. Gouzoulis, Yiping Zhang +4 more

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6

N/A

0.560DataRank · unranked

10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more